达帕格列嗪
糖尿病
视网膜
糖尿病性视网膜病变
视网膜
医学
内科学
内分泌学
药理学
2型糖尿病
眼科
生物
神经科学
作者
Qianyi Luo,Sameer P. Leley,Erika Bello,Hurshdeep Dhami,Deepa Mathew,Ashay D. Bhatwadekar
标识
DOI:10.1136/bmjdrc-2022-002801
摘要
Dapagliflozin, a sodium-glucose transporter inhibitor, effectively reduces blood glucose and is indicated for individuals with kidney diseases and cardiovascular disorders. In this study, we further expand the therapeutic benefit of dapagliflozin in the neural and vascular retina, with the potential to effectively manage diabetic retinopathy (DR), the most common complication of diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI